Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2018027526
pages 321-332

Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots

Malina Xiao
Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Muhammad Zaeem Noman
Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Ludovic Menard
Laboratory of Experimental Cancer Research, Department of Oncology; Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Andy Chevigne
Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Martyna Szpakowska
Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Manon Bosseler
Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Markus Ollert
Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg
Guy Berchem
Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg; Department of Hemato-Oncology, Centre Hospitalier de Luxembourg, L-1210 Luxembourg City, Luxembourg
Bassam Janji
Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg

RÉSUMÉ

Autophagy is a quality control process executed at the basal level in almost all cell types. However, in cancer cells, autophagy is activated by several stimuli, including hypoxia. Depending on tumor type, stage, and genetic context, autophagy is a double-edged sword. Autophagy promotes regression in newly established tumors; however, it supports tumor progression in well-established tumors by maintaining cancer cell survival under stress conditions. These data, in addition to the emerging role of autophagy in impairing antitumor immunity, have attracted significant interest in developing autophagy inhibitors as a new approach to cancer treatment. The enthusiasm for developing selective drugs inhibiting autophagy has been seriously challenged by the discovery that most autophagy-related proteins display nonautophagic functions. Autophagy inhibitors chloroquine and hydroxychloroquine are currently being investigated in several clinical trials in combination with standard anticancer therapies. Here, we provide a brief overview on the nonautophagic function of autophagy-related proteins and summarize the major mechanisms whereby autophagy modulation could positively or negatively impact cancer therapies. We also focus on the emerging role of targeting autophagy in the improvement of NK-mediated antitumor immunity through the regulation of CCL5 and its receptors' expression in melanoma, and we provide some clues revealing how autophagy modulators could be exploited to improve cancer immunotherapies.


Articles with similar content:

Therapeutic YY1 Inhibitors in Cancer: ALL in ONE
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Benjamin Bonavida
Angiogenesis: Promising Therapeutic Target of Metastatic Colon Cancer
Critical Reviews™ in Oncogenesis, Vol.25, 2020, issue 2
Rama Rao Malla, Rakshmitha Marni
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley
Regulation of the Cancer Stem Cell Phenotype by Raf Kinase Inhibitor Protein via Its Association with Kruppel-Like Factor 4
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Stephanie Wottrich , Benjamin Bonavida